A Review of PCSK9 Inhibitors and their effects on cardiovascular disease
Cardiovascular disease remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a major risk factor. Lower levels of LDL-C can effectively reduce the risk of cardiovascular disease. Proprotein convertase subtilisin/kexin t...
Saved in:
Published in | Current topics in medicinal chemistry |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
United Arab Emirates
08.08.2019
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Cardiovascular disease remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a major risk factor. Lower levels of LDL-C can effectively reduce the risk of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating the degradation of hepatic LDL receptors that remove LDL-C from the circulation. PCSK9 inhibitors are a new class of agents that are becoming increasingly important as treatments to reduce LDL-C levels. Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved to treat hypercholesterolemia and are available in the United States and European Union. Through inhibition of PCSK9 and increased recycling of LDL receptors, they can significantly reduce serum LDL-C levels.
This review will describe the chemistry, pharmacokinetics, and pharmacodynamics of PCSK9 inhibitors and their clinical effects. |
---|---|
AbstractList | Cardiovascular disease remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a major risk factor. Lower levels of LDL-C can effectively reduce the risk of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in regulating the degradation of hepatic LDL receptors that remove LDL-C from the circulation. PCSK9 inhibitors are a new class of agents that are becoming increasingly important as treatments to reduce LDL-C levels. Two PCSK9 inhibitors, alirocumab and evolocumab, have been approved to treat hypercholesterolemia and are available in the United States and European Union. Through inhibition of PCSK9 and increased recycling of LDL receptors, they can significantly reduce serum LDL-C levels.
This review will describe the chemistry, pharmacokinetics, and pharmacodynamics of PCSK9 inhibitors and their clinical effects. |
Author | Cui, Yanping Shi, Xin Zhao, Pengjun Chen, Bo Hou, Aiping |
Author_xml | – sequence: 1 givenname: Bo surname: Chen fullname: Chen, Bo organization: Department of Pediatric Cardiology, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 20092. China – sequence: 2 givenname: Pengjun surname: Zhao fullname: Zhao, Pengjun organization: Department of Pediatric, Shidong Hospital, Shanghai 20092. China – sequence: 3 givenname: Xin surname: Shi fullname: Shi, Xin organization: Department of Pediatric Cardiology, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 20092. China – sequence: 4 givenname: Yanping surname: Cui fullname: Cui, Yanping organization: Department of Pediatric Cardiology, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 20092. China – sequence: 5 givenname: Aiping surname: Hou fullname: Hou, Aiping organization: Department of Pediatric, Shidong Hospital, Shanghai 20092. China |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31400268$$D View this record in MEDLINE/PubMed |
BookMark | eNqFzcsKgkAUgOEhirLLK8R5ASEvlC5DCqNNVHs5OmfwgM7IjBq9fZtat_o3H_xLMdVG00R4QXKI_DhM47lYREG824X7xBP5Ee40Mr3AKLhlj2sKF11zyb2xDlBL6GtiC6QUVb0Do6FCK9mM6KqhQQuSHaGjtZgpbBxtvl2J7fn0zHK_G8qWZNFZbtG-i986_As-ZBc3ag |
ContentType | Journal Article |
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
DBID | NPM |
DatabaseName | PubMed |
DatabaseTitle | PubMed |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 1873-4294 |
ExternalDocumentID | 31400268 |
Genre | Journal Article |
GroupedDBID | NPM |
ID | FETCH-pubmed_primary_314002682 |
IngestDate | Fri Sep 17 18:52:55 EDT 2021 |
IsPeerReviewed | false |
IsScholarly | false |
Keywords | hypercholesterolemiProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors clinical effect Proprotein convertase subtilisin/kexin type 9 (PCSK9) pharmacokinetic hypercholesterolemia pharmacodynamic profile |
Language | English |
License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-pubmed_primary_314002682 |
PMID | 31400268 |
ParticipantIDs | pubmed_primary_31400268 |
PublicationCentury | 2000 |
PublicationDate | 2019-Aug-08 |
PublicationDateYYYYMMDD | 2019-08-08 |
PublicationDate_xml | – month: 08 year: 2019 text: 2019-Aug-08 day: 08 |
PublicationDecade | 2010 |
PublicationPlace | United Arab Emirates |
PublicationPlace_xml | – name: United Arab Emirates |
PublicationTitle | Current topics in medicinal chemistry |
PublicationTitleAlternate | Curr Top Med Chem |
PublicationYear | 2019 |
Score | 3.4910412 |
Snippet | Cardiovascular disease remains the leading cause of morbidity and mortality in the world, with elevated low density lipoprotein-cholesterol (LDL-C) levels as a... |
SourceID | pubmed |
SourceType | Index Database |
Title | A Review of PCSK9 Inhibitors and their effects on cardiovascular disease |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31400268 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwED-cguxFFL8_Rh58k0q7xrU-zqEUZUPYhPk02i3RDpYU6V78670kzdoNhx8vpVwgKfmld5fk7ncAl97Eo2M_CR2fUeqghXKdMI654_F4wl2fcperjWK314pe6OPwZliWvtPZJXlyPf78Nq_kP6iiDHFVWbJ_QHbRKQrwHfHFJyKMz19h3La8-CqQrdN_usXf_T1NUl1BpwiNTD_KmA2hiKir4afV65npMg1pLjNF4JwKe_2uiERsdbgyKMBorTtZOYCWJu5XvE3ni5XX17WDr4bpQtKZa8lrLDJrPYvDB5XvpPisje0wCjMMfAdtGq2qY5ylbKbn3Mf9G-7ywp9bV1ivbVMNakGoNFfvuVuHbSte2QRoZ2CwCzuFF0_aBpI92GBiH6I2MXAQyYmGg5RwEISDaDhIAQeRgizDQQo4DqDxcD_oRI4ZfJQZRpCR_azmIWwKKdgxEMpbSeyqtR4GtMmSOKDojjBGfRwDVd0JHK3p5HRtyxnUSxDOYYvjOmYX6BTlSUPP0BfU5xcP |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Review+of+PCSK9+Inhibitors+and+their+effects+on+cardiovascular+disease&rft.jtitle=Current+topics+in+medicinal+chemistry&rft.au=Chen%2C+Bo&rft.au=Zhao%2C+Pengjun&rft.au=Shi%2C+Xin&rft.au=Cui%2C+Yanping&rft.date=2019-08-08&rft.eissn=1873-4294&rft_id=info%3Apmid%2F31400268&rft_id=info%3Apmid%2F31400268&rft.externalDocID=31400268 |